Note 2 - Revenue (Details Textual) - Product [Member] - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Gross Net Accruals	$ 13.4	$ 28.1
Briumvi Ublituximab [Member]
Gross Net Accruals	$ 41.5